Related Experiment Video
Updated: Jul 4, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
[Surgical procedures in patients treated with platelet function inhibitors]
Hans-Jürgen Rupprecht1, Ralf Blank, Dorothee Konradi
1Medizinische Klinik, Klinikum Rüsselsheim, Rüsselsheim. hj.rupprecht@gp-ruesselsheim.de
Herz
|June 27, 2008
Summary
Platelet function inhibitors like aspirin and clopidogrel are crucial for preventing atherothrombotic events. Discontinuing these medications before surgery requires careful balancing of bleeding versus ischemic risks, especially post-stent implantation.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Context:
- Acetylsalicylic acid (ASA) and clopidogrel are widely prescribed platelet function inhibitors (PFIs).
- These agents are integral to managing various atherothrombotic diseases through mono- or dual antiplatelet therapy.
- Platelet inhibition persists for the entire platelet lifespan (10 days).
Purpose:
- To evaluate the critical balance between bleeding risks and ischemic complications when managing antiplatelet therapy around surgical procedures.
- To address the specific challenges posed by continued antiplatelet therapy after stent implantation, considering the risk of stent thrombosis.
Summary:
- Surgical procedures with low bleeding risks can often proceed with uninterrupted antiplatelet therapy.
- Higher bleeding risk procedures necessitate a careful consideration of partial or complete discontinuation of antiplatelet therapy.
- The decision-making process must weigh the potential for bleeding against the risk of ischemic events, particularly stent thrombosis.
Impact:
- Provides guidance for clinicians on managing antiplatelet therapy in patients undergoing surgery.
- Aims to optimize patient outcomes by minimizing both bleeding complications and thrombotic events.
- Highlights the importance of individualized risk assessment in perioperative antiplatelet management.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...